Business Context and Reporting Period
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral peptide-based therapies and an injectable hepcidin mimetic. The company reported unaudited results for the three months ended March 31, 2017, and operates as one segment.
- PTG-100: Global Phase 2b trial in moderate-to-severe ulcerative colitis, expected to complete in the second half of 2018.
- PTG-200: Preclinical development for Crohn’s disease, with Phase 1 expected in the second half of 2017.
- PTG-300: Preclinical development for iron-overload disorders, with Phase 1 expected in the second quarter of 2017.
- The company has no approved products and has generated no product revenue.
Financial Performance and Position
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Revenue | None | None | No product revenue in either period |
| Research and development expense | $11.3 million | $5.6 million | Up 101% |
| General and administrative expense | $3.0 million | $1.4 million | Up 111% |
| Total operating expenses | $14.3 million | $7.0 million | Up 103% |
| Net loss | $14.1 million | $11.7 million | Loss increased $2.4 million |
| Net loss per share | $0.84 | $40.96 | Per-share comparison affected by post-IPO share count |
| Cash used in operating activities | $10.4 million | $5.2 million | Use approximately doubled |
| Cash, cash equivalents and available-for-sale securities | $77.2 million | $87.7 million at Dec. 31, 2016 | Down $10.5 million |
Operating performance remained loss-making, so operating and net margins are not meaningful. Research and development spending increased primarily due to PTG-100 clinical development, preclinical work on other candidates, increased staffing, consultants and facility costs. General and administrative expense rose with headcount, professional services and public-company costs.
At March 31, 2017, the company had total assets of $82.7 million, current liabilities of $7.8 million, and stockholders’ equity of $74.9 million. Accumulated deficit was $78.7 million. The company had no outstanding debt or credit facility.
Cash flow included $1.3 million of net investing cash use, principally reflecting purchases of available-for-sale securities of $8.0 million offset by $6.8 million of maturities, and $0.4 million of financing cash inflow from stock option exercises and employee stock purchases. Stock-based compensation was $0.8 million.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $5.7 million, or 101%, to $11.3 million.
- General and administrative expense increased $1.6 million, or 111%, to $3.0 million.
- Net loss increased $2.4 million to $14.1 million, despite the absence of the $4.7 million preferred-stock tranche and warrant fair-value charge recorded in Q1 2016.
- Operating cash use increased from $5.2 million to $10.4 million, primarily reflecting higher operating spending and the absence of the large non-cash fair-value adjustments recorded in 2016.
- Cash, cash equivalents and marketable securities declined from $87.7 million at December 31, 2016 to $77.2 million at March 31, 2017.
- The company entered into an 84-month lease for a larger Newark, California office and laboratory facility. The filing’s contractual-obligation table reports total minimum lease payments of $13.817 million, while management’s narrative refers to approximately $13.5 million.
- The company early adopted the restricted-cash cash-flow presentation standard and adopted new share-based-payment guidance; management reported no material financial-statement impact other than presentation changes.
Outlook, Risks, Contingencies and Unusual Items
Management expects additional losses and negative cash flows for the foreseeable future. Based on its current operating plan, the company believes its cash, cash equivalents and available-for-sale securities will fund anticipated requirements for at least the next 12 months. However, substantial additional capital will be required to advance clinical development and commercialize any successful candidates, and financing may not be available on acceptable terms.
- Management expects research and development expenses to increase as PTG-100 advances and PTG-200, PTG-300 and discovery programs progress.
- The company has no product sales, approved products, or current collaborations for its product candidates.
- Product development depends on successful clinical trials, regulatory approvals, patient enrollment, third-party contract research organizations and contract manufacturers.
- In March 2017, the company filed a U.S. orphan-drug application for PTG-300 in beta-thalassemia; the application was still under FDA review at the reporting date.
- The company owes a former collaboration partner potential payments of up to $128.5 million for PTG-300 development, regulatory and sales milestones, plus a low-single-digit royalty on worldwide net sales, if applicable.
- The company continues to report two material weaknesses in internal control over financial reporting. Disclosure controls were not effective at the reasonable-assurance level as of March 31, 2017. Remediation included a new accounting system, additional accounting personnel, manual-journal-entry reviews and technical accounting support, but remediation was not complete.
- No material legal proceedings, unregistered securities sales, share repurchases or off-balance-sheet arrangements were reported.
Investor Verification Checklist
- Verify the pace, enrollment and results of the PTG-100 Phase 2b trial and whether the stated second-half-2018 completion target remains achievable.
- Verify initiation and regulatory status of planned Phase 1 studies for PTG-200 and PTG-300.
- Monitor quarterly cash burn, marketable-securities balances and the timing and terms of future financing.
- Reconcile the stated $13.5 million lease commitment with the contractual-obligation table total of $13.817 million.
- Assess progress in remediating the material weaknesses in internal control and whether additional deficiencies are identified.
- Review potential PTG-300 milestone and royalty obligations, intellectual-property rights and any future collaboration arrangements.
- Evaluate clinical, regulatory, manufacturing, competition, reimbursement and intellectual-property risks before relying on development timelines or future commercial potential.